Article citationsMore>>
Danne, T., Cariou, B., Banks, P., Brandle, M., Brath, H., Franek, E., et al. (2018) HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks with Sotagliflozin in Combination with Insulin in Adults with Type 1 Diabetes: The European Intandem2 Study. Diabetes Care, 41, 1981-1990.
https://doi.org/10.2337/dc18-0342
has been cited by the following article:
-
TITLE:
SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM
AUTHORS:
Rushi Patel, Terry Oroszi
KEYWORDS:
SGLT-2 Inhibitors, Type 2 Diabetes Mellitus, Cardiovascular Outcomes, Renal Protection, Glycemic Control
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.15 No.12,
December
30,
2024
ABSTRACT: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, safety, and potential benefits of SGLT-2 inhibitors in improving cardiovascular and renal outcomes in DM2 patients. A comprehensive review of clinical trials and studies on SGLT-2 inhibitors was conducted. SGLT-2 inhibitors significantly improve glycemic control, reduce cardiovascular mortality, and lower the risk of renal events in DM2 patients. SGLT-2 inhibitors offer substantial cardio-renal protection in DM2 management, though further research is needed to optimize their use.